Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Clinical trial NCT02060253 · COMPLETED

Trial details

NCT number: NCT02060253
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer

Start date: 2014-04-01
Primary completion: 2018-06-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.